Group 1 - The meeting between the Mayor of Nanjing, Li Zhongjun, and GE Healthcare's Global Executive Vice President, Song Weiqun, focused on enhancing collaboration in the medical technology sector [1] - GE Healthcare is recognized as a leading global medical technology company, with operations spanning medical imaging, digital healthcare, and drug development [1] - Both parties expressed commitment to leveraging their respective strengths to advance the nuclear medicine project and build a nuclear medicine ecosystem, aiming for high-quality development of Nanjing's biopharmaceutical industry [1]

Core Insights - The development logic of medical technology is shifting due to the upgrade of medical demand, engineering technology iteration, and the evolution of payment systems, with a focus on system-level solutions and industry collaboration [2] - The third Global MedTech Conference will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect engineering, clinical, corporate, capital, and regulatory aspects of medical technology innovation [2] - The conference will feature the release of a white paper, award evaluations, and multi-theme forums to present global medical technology innovation trends [2] Conference Overview - The conference will include a brand exhibition area for showcasing innovative technologies, products, and solutions, with reservations now open [3] - The second Global MedTech Conference highlighted the release of the "2026 Global Medical Technology Innovation White Paper" and awarded 11 innovation awards [4][6][7] - The white paper will provide a comprehensive framework for industry observation, focusing on technological evolution, product changes, corporate development models, and industry patterns [13][14] Key Themes - The white paper will cover high-end medical devices, surgical robots, medical imaging, digital healthcare, and the trends in registration and commercialization [15] - The conference will also feature awards for various categories, emphasizing long-term capabilities and systemic innovation [16][20] - Multi-theme forums will address topics such as medical technology innovation trends, engineering technology changes, and the commercialization path from R&D to market [17] Audience and Participation - The conference targets a diverse audience, including clinical experts, medical technology company leaders, industry observers, and investment representatives [21] - Sponsorship opportunities will provide structured, compliant, and sustainable collaboration paths for companies [22] - The event is positioned as an industry-focused, research-oriented conference rather than a purely academic or promotional meeting [23]

Core Viewpoint - The article discusses the issuance of measures by the Dongcheng District of Beijing to promote high-quality development in the pharmaceutical and health industry, highlighting the strategic importance of this sector in the context of China's health strategy [1]. Group 1: Policy Measures - The measures include support for traditional Chinese medicine, product innovation, enhancement of digital healthcare services, support for innovative pharmaceuticals, and optimization of talent services, comprising a total of 14 specific initiatives [1]. - The policies aim to provide a comprehensive support system that covers all key areas of industry development, focusing on high-end, intelligent, and green development [1]. Group 2: Financial Support - Significant financial support is established, with individual project funding reaching up to 20 million yuan, and a maximum of 10 million yuan per year for single entities in the medical device sector, effectively reducing innovation costs for enterprises [2]. - The funding is designed to stimulate innovation and accelerate the transformation of industry innovations into practical applications [2]. Group 3: Innovation Focus - The measures emphasize innovation-driven approaches, particularly in the digital transformation of traditional Chinese medicine and the development of digital healthcare service platforms [2]. - There is a strong focus on the application of artificial intelligence technologies in the health sector, aligning with trends in industry innovation and digital transformation [2].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing demand for mental health solutions in the region [1][4]. Group 1: Partnership Details - The collaboration will focus on establishing a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - The partnership includes applying for national innovation pilot projects, with Silk Road leading the engagement with Malaysian authorities [3]. - Clinical pilot projects will be initiated in selected hospitals, with the company responsible for local adaptation, training, and data collection [3]. Group 2: Market Context - Malaysia faces challenges with an aging population and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a counselor-to-population ratio of 1:52,000, far below the international standard of 1:500 [1]. Group 3: Strategic Importance - This partnership marks the company's official entry into the Malaysian market, expanding its Southeast Asian business network and leveraging its experience in the Chinese market [4]. - Silk Road's extensive local resources and networks will facilitate efficient product entry and market adaptation, enhancing commercial conversion rates [4]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and accelerate the deployment of its products in local medical institutions [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology to localize and promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry in the region [1][2]. Group 1: Market Context - Malaysia is facing challenges due to rapid population aging and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a psychological counseling ratio of 1:52,000, far below the international standard of 1:500, indicating a substantial market gap [1]. Group 2: Company Background - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first regulatory-approved digital therapy for cognitive impairment, included in the reimbursement catalog of provincial medical insurance in 30 provinces in China [1]. Group 3: Partnership Details - The partnership includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Technology assisting in local approvals and logistics while the company provides technical and research support [3]. - The collaboration will also involve applying for national innovation pilot projects, conducting clinical trials in selected hospitals, and jointly expanding market reach in Malaysia and other Southeast Asian countries like Indonesia, Thailand, and Vietnam [3]. Group 4: Strategic Benefits - This collaboration is expected to create long-term growth opportunities for the company and sustainable value for shareholders by expanding its international presence and leveraging local resources for efficient market entry [4]. - The partnership enhances the company's brand authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions and broadening its market in digital health management [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing mental health needs in the region [1][4]. Group 1: Partnership Details - The collaboration includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - Silk Road will lead the application for national innovation pilot projects, facilitating the company's engagement with Malaysian authorities [3]. - The partnership will also focus on clinical pilot projects in hospitals, with Silk Road identifying target hospitals and the company adapting products for local use [3]. - Both parties will work together to expand market presence in Malaysia and other Southeast Asian countries, including Indonesia, Thailand, and Vietnam [3]. Group 2: Market Context and Opportunities - Malaysia is facing challenges related to an aging population and increasing mental health demands, with 3.8 million people aged over 60 in 2023 and a significant shortage of mental health resources [1]. - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first approved digital therapy for cognitive impairment, already included in the reimbursement catalog of 30 provinces in China [1]. - The partnership is expected to enhance the company's international presence and brand influence, leveraging Silk Road's extensive local resources and networks in Malaysia to accelerate market entry and improve commercial conversion efficiency [4].

格隆汇2月5日丨脑动极光-B(06681.HK)宣布，公司与丝路之舟科技有限公司("丝路之舟")订立战略合作 协议，双方将在马来西亚及东南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化 等领域开展深度战略合作，共同推动数字健康产业发展。 根据协议，双方合作主要包括以下内容： (V)东南亚市场开拓合作：以马来西亚合作为基础，逐步拓展至印尼、泰国、越南等其他东南亚国家。 协议为双方就马来西亚及东南亚市场合作订立的框架协议，後续具体执行细节将由双方进一步约定实施 细则。 董事会相信，此次合作将为公司带来长期发展机遇，为股东创造可持续价值，具体而言： (I)深化国际化布局，拓展海外市场：公司已先後在中国香港、澳门及新加坡开展业务推广及运营，积累 海外市场经验。本次与丝路之舟合作，标志着公司正式进入马来西亚市场，进一步拓展东南亚业务网 络，有助于将公司在中国市场验证的数字疗法经验与技术体系系统性地输出至具备成长潜力与政策支持 的区域市场，进一步扩大公司在国际上的品牌影响力与业务覆盖，提升全球影响力。 (II)借助本地资源，加速市场落地：丝路之舟在马来西亚拥有丰富的政府与医疗资源网络，可协助公司 高效完成 ...

BrainAurora Medical Technology Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6681） 自願公告 訂立戰略合作協議以拓展馬來西亞市場及深化國際化布局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發布的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣布，本公司與絲路之舟科技有限公司（「絲路之 舟」）訂立戰略合作協議（「協議」），雙方將在馬來西亞及東南亞區域圍繞認知障礙 數字療法產品的本土化落地、市場推廣與科研轉化等領域開展深度戰略合作，共 同推動數字健康產業發展。 合作背景與內容 馬來西亞為東南亞重要經濟體之一，正面臨快速人口老化及精神健康需求攀升 的挑戰。根據馬來西亞統計局數據，2023年該國60歲以上人口達380萬。與此同 時，青少年心理健康問題亦日益突出。馬來西亞政府雖已推動多項精神健康政 策，然診療資源仍顯稀 ...

Group 1 - The "International Digital Economy Governance and Leading Talent Capacity Building Project" has officially launched at Beijing University of Science and Technology, aimed at sharing Beijing's digital economy practices with representatives from 17 countries to enhance digital transformation capabilities in developing nations [1][2] - The project is co-hosted by the United Nations Institute for Training and Research, the Global Digital Economy Cities Alliance, and local government bodies, lasting for 9 days [1] - Participants will focus on cutting-edge topics such as digital governance, AI ethics, smart transportation, and digital healthcare, with immersive learning experiences through workshops and visits to notable Beijing companies [1] Group 2 - The program includes 8 sessions of country-specific storytelling on digital economy governance and industry needs, fostering deep dialogue among participants to promote cross-border collaboration [2] - Beijing aims to accelerate its development as a global digital economy benchmark city, with plans to issue the "Global Digital Friendly Initiative" by 2025, showcasing a unique "Beijing Solution" and "Beijing Experience" [2] - The project is expected to serve as a catalyst for building an international digital cooperation network, contributing to the sustainable development of the global digital economy [2]

DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 ("Period"). Administration costs decreased by 5% in the Period (H1 2024 - ...